Pharmaceutical Technology Transfer: How to Know Whether a Product Is Really Ready to Move

Technology transfer is often described as the movement of a process from one site to another. That description is accurate, but incomplete. 

A pharmaceutical technology transfer is really the transfer of knowledge, control and accountability. Equipment, methods and documents can be moved relatively quickly. The harder task is ensuring that the receiving organisation understands the product and process well enough to reproduce it consistently, investigate problems intelligently and maintain control after the sending team steps away. 

That is why apparently well-planned transfers can still run into difficulty late in the programme. 

The project plan may show that documents have been issued, methods transferred, validation activity scheduled and batches booked. Yet unresolved technical assumptions, weak knowledge capture or unclear ownership can remain hidden until engineering, PPQ, registration or commercial supply. 

The most important question is therefore not, "Have we transferred the documents?" 

It is, "Has the receiving organisation acquired enough knowledge and control to operate the process successfully?" 

Technology transfer is not a document handover 

Documentation is fundamental to pharmaceutical manufacturing. 

Specifications, methods, process descriptions, batch records, validation reports, development reports, risk assessments and change controls all contribute to the technical package. But a document cannot always explain why a process behaves the way it does. Experienced teams often carry a significant amount of tacit knowledge. They know which parameter appears wide in the manufacturing instruction but is operationally sensitive. They know which raw material attribute tends to create variability. They know that a particular analytical result is usually the first indication that the process is drifting. They know which equipment differences matter and which do not. If that knowledge is not identified and transferred, the receiving site may technically follow the process while missing the information that allows experienced judgement. Good technology transfer therefore creates structured opportunities to expose assumptions, explain historical challenges and capture the rationale behind decisions. 

Start with product and process understanding 

Before a transfer plan is built, the programme should establish what is already known about the product. That includes understanding the critical quality attributes, process parameters, material attributes, analytical methods, control strategy, development history and known sources of variability. The maturity of that knowledge matters. A long-established commercial product with extensive process history presents a different challenge from a product moving rapidly from development into clinical or commercial manufacture. The latter may still contain uncertainty. Specifications may be evolving. Process ranges may be based on limited data. Analytical methods may have unresolved robustness issues. The control strategy may still be developing. Technology transfer does not remove those uncertainties. It moves them. If they are not made visible, the receiving site can inherit risks that were never properly understood by either party. A readiness assessment should therefore identify both what is known and what is not yet known. 

The receiving site matters as much as the sending site 

A transfer is not successful because the sending site can manufacture the product. 

The receiving site has to be capable of doing so within its own environment. That means assessing facility design, equipment, utilities, automation, laboratory capability, materials, personnel, quality systems and local operating practices. Equipment described as equivalent can still behave differently. Scale can change mixing, heat transfer, hold times and sampling; different laboratory platforms can create analytical-transfer challenges. Organisational structure matters too. Responsibilities split differently between Manufacturing, Engineering, Validation, MS&T and Quality can create gaps in ownership or communication. A credible gap assessment examines how the intended process fits the actual receiving environment rather than assuming equivalence. 

Do not wait until validation to find the gaps 

Validation is expensive and highly visible. 

It should not be the first time the organisation discovers that important technical questions remain unanswered. The strongest technology-transfer programmes use earlier phases to test assumptions. Engineering batches, method-transfer activity, equipment trials, small-scale studies and structured technical reviews can all expose issues while there is still time to respond. The purpose is not to eliminate every possible problem. That is unrealistic. It is to identify the problems that can reasonably be anticipated before they appear during a critical validation or supply milestone. This requires active technical ownership. A programme manager can coordinate timelines and actions, but technology transfer also needs people able to challenge whether the evidence actually supports progression. That is where CMC and MS&T expertise becomes especially valuable. 

What should a transfer readiness review examine? 

A useful readiness review should look across the full technical system rather than focusing on one workstream. 

The product knowledge package is one area. Are development reports complete? Are critical assumptions documented? Are historical deviations, atypical results and investigations available? Is the control strategy clear? 

Manufacturing readiness is another. Is the process mapped to the receiving equipment and facility? Have scale or equipment differences been assessed? Are batch records sufficiently detailed and usable? Are materials and suppliers qualified? Analytical readiness is equally important. Have methods been transferred or verified appropriately? Are reference standards, reagents, system suitability requirements and laboratory procedures available? Does the receiving laboratory understand known method sensitivities? Validation readiness should also be tested. Are the prerequisites for process validation complete? Are protocols based on current process knowledge? Are acceptance criteria scientifically justified? Are outstanding changes or deviations likely to affect execution? Regulatory alignment cannot be treated as a later administrative step. The organisation needs to understand what has been filed, what is approved, what commitments exist and whether the receiving-site process creates variation or submission requirements. Finally, governance needs to be clear. Who owns each decision? Who can approve progression? How are risks escalated? What happens when the sending and receiving organisations disagree? If those questions cannot be answered, the programme may be scheduled but it is not necessarily ready. 

CMC, MS&T, Quality and Regulatory need to work as one system 

Technology-transfer programmes are vulnerable when functional workstreams operate independently. CMC may understand the product history. MS&T may own process transfer. Quality may oversee validation and deviations. Regulatory Affairs may manage filing commitments. Supply Chain may be focused on launch dates and inventory. Each team can perform its own work correctly and the programme can still fail at the interfaces. For example, an equipment change may be technically acceptable but create a regulatory filing requirement. An analytical-method adjustment may resolve a laboratory problem while affecting comparability. A proposed deviation response may allow a batch to progress but expose a weakness in the broader control strategy. The programme therefore needs integrated technical governance. Decisions should be assessed for product, quality, manufacturing and regulatory impact together. This is particularly important in accelerated programmes, where pressure to protect the timeline can encourage teams to close actions in isolation. 

A transfer plan should include decision points, not just tasks 

Many technology-transfer plans are detailed lists of activity. Documents to issue. Methods to transfer. protocols to approve. Training to complete. Batches to schedule. 

Those tasks are necessary, but the plan also needs meaningful decision gates. 

Before the next stage begins, what evidence needs to exist? 

What risks are acceptable to carry forward? 

Which open actions genuinely block progression? 

Who has the authority to make the decision? 

Without defined gates, programmes can drift forward because the calendar says they should, rather than because the technical evidence supports it. That often leads to a concentration of unresolved issues immediately before validation, filing or launch. A robust programme makes readiness visible. 

What happens when transfer activity starts to go wrong? 

Most transfer problems do not require panic. 

They require structure. 

The first step is to understand whether the issue is isolated or systemic. A failed engineering batch may be caused by a specific execution error. It may also reveal that the process understanding is weaker than expected. An unsuccessful method transfer may reflect analyst technique. It may expose a method that was never sufficiently robust. A validation deviation may be manageable within the established control strategy. Or it may challenge the underlying process assumptions. The response therefore needs disciplined triage. What happened? What is the product impact? What does the existing data show? Is the event understood? What other activities are affected? Does the programme need to pause? The quality of those decisions matters more than the desire to preserve the original timeline. Schedule pressure should not become scientific justification. 

Know when additional technical resource is needed 

Technology transfers can place disproportionate demand on internal teams. The organisation still has routine manufacturing, investigations, regulatory commitments and existing products to manage while the transfer generates a second layer of technical work. That can create a capacity problem even when the internal team has the right expertise. In other situations, the capability gap is specialist rather than numerical. The company may need experienced CMC input, MS&T leadership, analytical expertise, regulatory strategy or independent technical challenge for a defined phase of the programme. External support can be used in different ways. It might provide a targeted readiness assessment before transfer starts, additional technical resource through execution, independent review of critical packages, support with deviations and investigations, or longer-term outsourced CMC and MS&T capability. TDP's Consulting and Enterprise services support organisations across CMC, MS&T, Regulatory Affairs, quality systems and outsourced departmental functions, allowing the delivery model to match the scale and maturity of the programme. The objective should not be to create another advisory layer. It should be to close specific gaps in ownership, expertise or delivery. 

The final stage: prove the process can be owned 

A successful technology transfer is not simply the completion of validation batches. The receiving organisation should be able to demonstrate that it can manage the product after formal transfer activity ends. 

Can it interpret process data? 

Can it investigate deviations without relying on the sending site? 

Can it assess changes intelligently? 

Can it maintain the validated state? 

Can it explain the control strategy to an inspector? 

Can it identify when performance is drifting? 

That is the real test of transfer. If the receiving site can only operate successfully while the original experts remain continuously involved, knowledge has not yet been fully transferred. 

Build transfer around understanding, not movement 

Technology transfer will always involve project plans, document packages, protocols and timelines. But those are the mechanisms of transfer, not the outcome. The outcome is a receiving organisation with sufficient knowledge, capability and governance to control the product and process consistently. That requires earlier identification of uncertainty, honest assessment of site differences, integrated CMC, MS&T, Quality and Regulatory decision-making and clear evidence-based progression gates. The strongest programmes do not ask only whether the next activity is scheduled. They ask whether the organisation has earned the right to move to the next stage. Because once commercial or clinical supply depends on the receiving site, the cost of discovering a hidden gap rises very quickly. 

How TDP can help 

If you need practical support strengthening your pharmaceutical quality, regulatory or operational model, TDP can provide the right expertise at the right time. Request a call back to discuss where support would create the most value.